Velsera’s Post

Poll Time! Let's hear from you! Request a demo to see these features live!    https://lnkd.in/gs_vENBa

Velsera is excited to announce the launch of CGW Plus, our reimagined Clinical Genomics Workspace!  CGW Plus is set to revolutionize genetic sequence data analysis and reporting with its advanced variant quality and clinical evidence review workflows. Designed to simplify and accelerate processes, it ensures clinical laboratory professionals have the most accurate data at their fingertips. Key features include:  🔸 Expanded clinical and biological evidence review capabilities  🔸 Automated draft interpretive text for streamlined reporting  🔸 Comprehensive molecular results reporting  🔸 Adaptive learning and memory features  🔸 Dynamic PDF report rendering  🔸 Location-aware clinical trial matching interface  Learn more about how CGW Plus can transform your clinical genomics workflow. Read the full press release for all the details! https://lnkd.in/e22emaMS  #ClinicalGenomics #EraOfVelsera #CGWPlus #PrecisionMedicine 

Hold on tight! NGS Reimbursement Coverage is Changing Fast! Are You Ready? Our team of reimbursement specialists is here to guide you with their years of experience and knowledge of the ever-changing landscape of NGS reimbursement. If you want to learn about: 🔸 Revised 2024 CPT codes 🔸 The Medicare Gapfill process 🔸 Biomarker legislation 🔸 How Velsera can help you with assay design, validation, and testing coverage Watch the free session today! https://lnkd.in/gZxHhrxk #EraOfVelsera #NGS #Reimbursement #CPT #MolDx

Strategic selection of tests to develop in your clinical molecular lab is crucial, especially with the FDA's new final rule on laboratory developed tests (LDTs).   At Velsera, we are here to guide you through these changes. Essential areas for learning include: 🔸 FDA Requirements: Understand the new compliance standards for your lab's tests.  🔸 Current and Future Test Offerings: Learn how these regulations impact your ongoing and upcoming test development plans.  🔸 Kitted IVD Solutions: Explore the benefits of FDA-cleared or -approved options versus developing your own tests.  🔸 Exemptions: Find out about specific exemptions and whether they may apply to your lab. Navigating these changes is essential for ensuring your lab's success and continued service to patients and clinicians. We've supported many labs through compliance transitions and are confident we can help you, too. Prepare your lab for the future and ensure you're on the right path. Read the full blog now to stay ahead of the curve and make informed decisions for your molecular lab. https://lnkd.in/ebSGUgXf #MolecularLab #LDT #FDACompliance #ClinicalTesting 

Today, we celebrate Juneteenth, a day of profound significance in American history. On June 19, 1865, the last enslaved African Americans in Galveston, Texas, learned of their freedom—over two years after the Emancipation Proclamation was issued. Juneteenth is a powerful reminder of our nation’s journey toward freedom and equality. While we acknowledge the progress made, we also recognize the ongoing struggle for full rights and justice for all. Here are some meaningful ways to honor Juneteenth in our professional lives: 🔸 Educate ourselves and others about the history and significance of Juneteenth. 🔸 Advocate for policies and practices that promote diversity, equity, and inclusion. Happy #Juneteenth!

Join us on June 26 at 2:00 PM EDT for the second part of our series on the canine cancer research model! 🐶🧬 Recent breakthroughs in both “wet” and “dry” labs have led to valuable new methods for sample collection and diagnosis, breed prediction and classification, and tumor microenvironment and genetic analysis. These advances promise better outcomes for both dogs and humans. Our webinar features: 🔸 Dr. Shaying Zhao will discuss her lab’s innovative bioinformatic research methods in comparative oncology in her talk titled “MHC Genotyping, Tumor-Specific Neoantigen Discovery, and T Cell Repertoire Characterization for the Dog.” 🔸 Dr. Heather Gardner will share developments in minimally invasive diagnostic techniques in her talk titled “Considerations for Longitudinal Liquid Biopsy Analysis in Spontaneous Canine Cancers.” Register to learn the latest advancements in canine cancer research: https://lnkd.in/g3a-xwuD #CancerResearch #Webinar #CancerGenomicsCloud

Join us on June 18 at 12 PM ET for our webinar: "Alterations in the Tumor Microenvironment and Key Signaling Pathways in Canine Gliomas Mirror Those Seen in Human Patients." In this webinar, Nadia Lanman, PhD, research associate professor in the department of comparative pathobiology at Purdue University, will discuss her work comparing naturally occurring canine and human gliomas. She will focus on the tumor microenvironment (TME) and key pathways dysregulated in human gliomas. Reserve your spot today! https://lnkd.in/gbnHb_JU #CancerResearch #Gliomas #SignalingPathways #EraofVelsera

Our Chief Science Officer, Jack DiGiovanna, joined nearly 2000 riders on #NationalCancerSurvivorDay, cycling from the Ben Franklin Bridge to the Jersey Shore in the American Cancer Society's #BridgeToBeachRide. This #century ride (100 miles) honors survivors and remembers those we have lost. Thanks to the participants and their supporters, the event collectively raised almost $1 million for patient care and cancer research.   #CancerResearch #CancerAwareness

We know that the FDA’s Final Rule on enforcing IVD (in vitro diagnostic) regulations for Laboratory Developed Tests raises many questions and concerns about the future of LDTs and how laboratories will navigate these changes. At Velsera, we’re dedicated to supporting our community of labs during this regulatory transition. Explore some of our resources for more information on navigating these dynamic landscapes: https://lnkd.in/g9Q2U9ea #FDARuling #LDT #LabRegulations #IVD #PatientCare